.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech intend to provide on the Nasdaq under the symbol "BIOA," depending on to files submitted with the Stocks as well as Exchange Commission. The business has actually not publicly discussed an expected financial volume for the offering.The clinical-stage provider boasts lead candidate azelaprag, an orally supplied small molecule slated to enter phase 2 testing in combination along with semaglutide-- offered by Novo Nordisk under brand name Wegovy for weight management-- in the very first fifty percent of following year. Semaglutide is likewise sold as Ozempic and also Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually developed to integrate well along with GLP-1 medicines, enhancing fat loss while protecting muscular tissue mass. The investigational medication was located to be well-tolerated amongst 265 people throughout 8 phase 1 trials, according to BioAge.Formerly, BioAge amassed the assistance of Lilly to operate a test mixing azelaprag with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro as well as Zepbound for fat loss. The partners are actually presently performing a stage 2 trial of azelaprag and also tirzepatide, along with topline results anticipated in the third quarter of 2025.The biotech is also considering an insulin sensitiveness proof-of-concept trial evaluating azelaprag as a monotherapy in the initial fifty percent of following year to sustain prospective indicator growth. On top of that, the company prepares to talk to the FDA for approval in the second fifty percent of 2025 to release human testing for an NLRP3 prevention targeting metabolic ailments and also neuroinflammation.BioAge's foreseed transfer to the public market follows a mild uptick in organized biotech IPOs from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the current IPO garden is actually a "combined picture," along with top quality firms still debuting on everyone markets, only in lessened varieties, depending on to PitchBook.